Abstract
BACKGROUND Testing for antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been instrumental in detecting previous exposures and analyzing vaccine-elicited immune responses. Here, we describe a scalable “Made-in-Canada” solution that can detect and quantify SARS-CoV-2 antibodies, discriminate between natural infection- and vaccination-induced responses, and assess antibody-mediated inhibition of the spike-angiotensin converting enzyme 2 (ACE2) interaction.
METHODS We developed a set of methods and reagents to detect SARS-CoV-2 antibodies by enzyme-linked immunosorbent assay (ELISA). The main assays focus on the parallel detection of immunoglobulin (Ig)Gs against the spike trimer, its receptor binding domain (RBD), and the nucleocapsid (N) protein. These antigens are complemented by a detection antibody (human anti-IgG fused to horseradish peroxidase (HRP)) and a positive control reference antibody (recombinant IgG against the RBD), permitting intra- and inter-laboratory comparisons. Using this toolkit and commercial reagents, we optimized automated ELISAs on two different high throughput platforms to measure antibody responses to SARS-CoV-2 antigens. The assays were calibrated to a reference standard from the World Health Organization. We also automated a surrogate neutralization (sn)ELISA that measures inhibition of ACE2-Spike or -RBD interactions by antibodies using biotinylated ACE2.
RESULTS Our individual IgG-based ELISAs measure antibody levels in single-point measurements in reference to a standard antibody curve to accurately distinguish non-infected and infected individuals (area under the curve > 0.96 for each assay). Positivity thresholds can be established in individual assays using precision-recall analysis (e.g., by fixing the false positive rate), or more stringently, by scoring against the distribution of the means of negative samples across multiple assays performed over several months. For seroprevalence assessment (in a non-vaccinated cohort), classifying a sample as positive if antibodies were detected for at least 2 of the 3 antigens provided the highest specificity. In vaccinated cohorts, increases in anti-spike and -RBD (but not -N) antibodies are observed. Here, we present detailed protocols to perform these assays using either serum/plasma or dried blood spots both manually and on two automated platforms, and to express the results in international units to facilitate data harmonization and inter-study comparisons. We also demonstrate that the snELISA can be performed automatically at single points, increasing the scalability of this functional assay for large seroprevalence studies.
INTERPRETATION The ability to measure antibodies to three viral antigens and identify neutralizing antibodies capable of disrupting spike-ACE2 interactions in high-throughput assays enables large-scale analyses of humoral immune responses to SARS-CoV-2 infection and vaccination. The “Made-in-Canada” set of protein reagents, produced at the National Research Council of Canada are publicly available to enable the up-scaling of standardized serological assays, permitting nationwide data comparison and aggregation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We acknowledge support from Ontario Together and funding from the Canadian Institutes of Health Research (CIHR; #VR1-172711 and #439999) and the COVID-19 Immunity Task Force (CITF). We also acknowledge financial support from the NRC Pandemic Response Challenge Program. Funding for initial assay development in the Gingras lab was provided through generous donations from the Royal Bank of Canada and the Krembil Foundation to the Sinai Health System Foundation. The robotics equipment used is housed in the Network Biology Collaborative Centre at the LTRI, a facility supported by the Canada Foundation for Innovation, the Ontario Government, and Genome Canada and Ontario Genomics (OGI-139). Assay development in the Langlois lab and the purchase of robotic equipment was supported by a grant from the CIHR (#VR2-172722) and supplemental funding from the CITF. Kento T. Abe was a recipient of an Ontario Graduate Scholarship and is supported by a CIHR CGS-D studentship. Mariam Maltseva holds a Queen Elizabeth II Graduate Scholarship in Science and Technology (QEII-GSST).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Research Ethics Board of Mount Sinai Hospital (Toronto, ON) gave ethics approval for performing ELISA assays with samples collected across several studies (study number: #20-0078-E). The Research Ethics Board of Mount Sinai Hospital also gave ethics approval for sample collection and analysis (studies #02-0118-U/05-0016-C, #01-0138-U, #20-0144-A, #21-0049-E and #01-0347-U). The Research Ethics Board of the Unity Health Network (Toronto, ON) gave ethics approval for sample collection and analysis (study #20-044). The Research Ethics Board of Sunnybrook Health Sciences Centre gave ethics approval for sample collection and analysis (study #4814). The British Columbia Childrens Hospital Biobank (BCCHB) in Vancouver, BC, Canada gave approval sample collection and analysis (REB#: H-07-20-6009). The University of Ottawa gave ethics approval for sample collection and analysis (REB # H-04-20-5727, # H-11-20-6172 and REB # H-09-20-6135).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The authors declare no competing interests
Funding: We acknowledge support from Ontario Together and funding from the Canadian Institutes of Health Research (CIHR; #VR1-172711 and #439999) and the COVID-19 Immunity Task Force (CITF). We also acknowledge financial support from the NRC’s Pandemic Response Challenge Program. Funding for initial assay development in the Gingras lab was provided through generous donations from the Royal Bank of Canada and the Krembil Foundation to the Sinai Health System Foundation. The robotics equipment used is housed in the Network Biology Collaborative Centre at the LTRI, a facility supported by the Canada Foundation for Innovation, the Ontario Government, and Genome Canada and Ontario Genomics (OGI-139). Assay development in the Langlois lab and the purchase of robotic equipment was supported by a grant from the CIHR (#VR2-172722) and supplemental funding from the CITF. Kento T. Abe was a recipient of an Ontario Graduate Scholarship and is supported by a CIHR CGS-D studentship. Mariam Maltseva holds a Queen Elizabeth II Graduate Scholarship in Science and Technology (QEII-GSST).
Data Availability
This is a methods development manuscript. REAGENT ACCESS: The reagents produced by the NRC and qualified as reference materials (SMT1-1, N and hACE2-BAP) are available through the Metrology Research Centre Virtual Store (Virtual Store - National Research Council Canada: Products in Category Proteins (nrc-cnrc.gc.ca)). A limited panel of matched plasma and DBS is available upon request
